The BCMA-targeting humanized bispecific monoclonal antibody elranatamab elicited high response rates when subcutaneously delivered at higher doses in patients with relapsed/refractory multiple myeloma.
Recent Content
- Multiple myeloma incidence, transplant utilization, and mortality- impact of social vulnerability
- Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
- Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis
- Automated radiomics model for prediction of therapy response and minimal residual disease from baseline MRI in multiple myeloma
- Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis
- Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses
- Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)
- (no title)
- The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review
- (no title)